Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1

Next Previous
Trial Profile

A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maraviroc (Primary) ; Darunavir; Emtricitabine; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Pharmacodynamics

Most Recent Events

  • 09 Sep 2022 Results assessing levels of the lysosomal cysteine protease cathepsin B (CatB), and its endogenous inhibitor cystatin B (CysB) were altered in PWH with neurocognitive impairment, and if antiretroviral therapy (ART) further influenced these levels, published in the JAIDS.
  • 20 Jun 2016 Results assessing neurocognition published in the AIDS.
  • 08 Jun 2016 Results assessing whether maraviroc has differential effects on CD4 count and CD4: CD8 ratio normalization compared to TDF (n = 230) published in the AIDS.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top